Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
April 8, 2021: PrEP “contemplation” and uptake among adolescents; adolescent perception of HIV risk; HIV diagnosis rates among transgender people; PrEP and HIV incidence in Scotland.
Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
Researchers recommend PrEP programs be linked to a gender-affirming care clinic, to build trust and retain patients in care.
CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.
March 18, 2021: Improving viral suppression among PLWH experiencing homelessness; co-located PrEP services for trans women; subsidized health care and PrEP uptake; Heplisav-B hepatitis B vaccine efficacy in PLWH.
From new forms of PrEP to new data on HIV in the U.S., CROI 2021 has plenty of developments to report when it comes to preventing HIV and better understanding the drivers of the modern epidemic.
March 4, 2021: Improving care for PLWH in transition from incarceration; long-acting PrEP's potential in Black and Latinx communities; comorbidity rates and COVID-19 risk among PLWH; how COVID lockdowns affect the HIV epidemic.
Beyond the big-picture improvements, a closer look at the data reveals stark racial and geographic disparities in HIV incidence and prevalence.